HOME
기자가 쓴 기사 더보기
(편집자 주 - 2010년 9월 25일 미국 FDA에서 보내온 에포젠 (Epogen) 과 프로크리트 (Procrit) 리콜 관련 내용입니다.)
Epogen and Procrit (epoetin alfa): Recall - Particulate Matter in Vials
AUDIENCE: Risk Manager, Oncology, Nephrology
ISSUE: Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely visible.
The potential serious adverse events resulting from the use of a sterile injectable product with particulates by the intravenous route include embolic, thrombotic and other vascular events (e.g., phlebitis), and by the subcutaneous route include foreign body granuloma, local injection site reactions, and increased immunogenicity.
BACKGROUND: The products are indicated for the treatment of anemia related to HIV therapy, chronic renal failure, and chemotherapy.
The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.
The affected product lot numbers and expiration dates are included in the table in the firm press release.
RECOMMENDATIONS: Amgen has initiated recall letters which include instructions to return the referenced product to the returned goods service provider.
| 인기기사 | 더보기 + |
-
1 베일 벗은 에이비엘바이오 비장의 카드㊤ siRNA와 그랩바디-B -
2 메지온 "희귀소아질환 '신속심사바우처'부활,미국 대통령 최종 승인" -
3 파킨슨병 권위자 한자리에…“이제는 임상에서 답해야 할 때” -
4 보로노이,비소세포폐암 환자 'VRN110755' 임상1상 IND 호주 승인 -
5 "염증·혈관·섬유화·세포치료" 신장병 극복 K-바이오 4색 전략 -
6 베일 벗은 에이비엘바이오 비장의 카드㊦ siRNA가 ‘꿈의 기술’인 이유 -
7 "파킨슨병 정복, 도파민 보충 넘어 질환 조절 패러다임 바뀐다" -
8 아미코젠, 인도 대리점 Aruni 통해 IEX 레진 첫 상업용 수주 확보 -
9 케어젠, 신규 전달 기술 '히알루로니다제 펩타이드' 최초 공개 -
10 "국내 최초 AI 기반 PK·PD 모델링 특화 기업 'APLUS 시뮬레이션' 등장"
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |
|
서울시 서초구 서초대로 115 정다운빌딩 4층 TEL : 02-3270-0114 FAX : 02-3270-0189 E-mail : webmaster@yakup.com |
발행일 : 1954. 03. 29 등록일 : 2016. 05. 02 대표이사 : 함태원 발행 · 편집인 : 함태원 등록번호 : 서울,아04071 |
사업자등록번호 : 106-81-10940 통신사업자신고번호 : 제2022-서울서초-2586호 청소년보호책임자 : 이종운
Copyright © Yakup.com All rights reserved.
|
- 약업신문 편집국 기자 news@yakup.com
- 입력 2010.09.26 02:16 수정 2010.09.26 03:39
(편집자 주 - 2010년 9월 25일 미국 FDA에서 보내온 에포젠 (Epogen) 과 프로크리트 (Procrit) 리콜 관련 내용입니다.)
Epogen and Procrit (epoetin alfa): Recall - Particulate Matter in Vials
AUDIENCE: Risk Manager, Oncology, Nephrology
ISSUE: Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely visible.
The potential serious adverse events resulting from the use of a sterile injectable product with particulates by the intravenous route include embolic, thrombotic and other vascular events (e.g., phlebitis), and by the subcutaneous route include foreign body granuloma, local injection site reactions, and increased immunogenicity.
BACKGROUND: The products are indicated for the treatment of anemia related to HIV therapy, chronic renal failure, and chemotherapy.
The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.
The affected product lot numbers and expiration dates are included in the table in the firm press release.
RECOMMENDATIONS: Amgen has initiated recall letters which include instructions to return the referenced product to the returned goods service provider.
무단 전재·복사·배포 등을 금지합니다.